Rubbing my ball, page-849

Imugene’s Disruption

It’s no question Imugene is hoping to disrupt the cancer treatment space. We hope it does. This could mean massive improvements compared to invasive cancer treatments in use today.

The B-cell platform is aiming to supersede current monoclonal antibody therapies due to better safety, efficacy, practicality and cost. These incumbent immunotherapies include:

• Keytruda ~$12 billion annual sales
• Herceptin ~$6 billion annual sales
• Opdivo ~$8 billion annual sales
• Tecentriq ~3 billion annual sales

Keytruda 9000 bucks a jab HER-Vaxx nearly there

balls will be ring a ding dinging soon